Beth Karlan, MD
Gynecologic Oncology · Los Angeles, CANPI 1609859586
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Merck accounts for 65.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $15,379 and has fallen 99.2% since, to $128 in 2024.
Across 22 payments — averaging $1237.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- Foundation Medicine, Inc.$7K
- F. Hoffmann-la Roche AG$2K
- GSK$157
- Seagen Inc.$155
- Pacira Pharmaceuticals Incorporated$128
What the payments were for
- Consulting fees$11,81043%
- Speaking & faculty fees$6,50824%
- Travel & lodging$8,25130%
- Food & beverage$6642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $17,879 |
| Foundation Medicine, Inc. | 2 | $6,603 |
| F. Hoffmann-la Roche AG | 1 | $2,310 |
| GSK | 2 | $157 |
| Seagen Inc. | 1 | $155 |
| Pacira Pharmaceuticals Incorporated | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,232 in reported general payments places this provider in the 85th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Los Angeles
- Dana ChaseLos Angeles$1.3M
- Melissa HodeibLos Angeles$19K
- Eijean WuLos Angeles$15K
- Xiaoyue GuoLos Angeles$4K
- Huyen PhamLos Angeles$4K
- John ChanSan Francisco$2M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.